Illumina closes $350M diagnostics buy; Plaintiff in SD says J&J vaginal mesh caused pain and suffering;

 @FierceMedDev: Abbott chops 200 jobs at Ireland plant. Story | Follow @FierceMedDev

 @MarkHFierce: A cancer diagnostic test you could use yourself in the bathroom at home? It's coming... More | Follow @MarkHFierce

 @DamianFierce: Despite a revenue jump, Volcano's profits tanked in Q4. News | Follow @DamianFierce

> Illumina ($ILMN) has wrapped up its $350 million acquisition of Verinata Health, maker of fetal chromosomal diagnostics. News

> Lab21 is partnering with IntegraGen, planning to use that company's biomarkers to develop a microRNA assay for colorectal cancer. More

> As India worries about the spread of swine flu, Qiagen ($QGEN) has launched Madhya Pradesh's first molecular diagnostics lab, saying DNA detection could help predict mutations of the virus and decrease rates of infection. Article

> Johnson & Johnson ($JNJ) is facing thousands of lawsuits over its discontinued Gynecare Prolift vaginal mesh, and a plaintiff in South Dakota has testified that the device resulted in pain, tissue damage and 18 subsequent surgeries. Story

> According to a new study, most women are misinformed about intrauterine devices (IUDs), which are more effective as a contraceptive option than birth control pills, researchers say. Report

> The FDA is proposing a new rule that would require devicemakers to submit information on how their products affect pediatric patients even if the devices are designed for adults. News

Biotech News

 @FierceBiotech: FDA approved T-DM1 for patients with HER2-positive breast cancer. Story | Follow @FierceBiotech

@JohnCFierce: Elan lines up biotech deals as it preps for $3B Tysabri windfall. Report | Follow @JohnCFierce

> Report: Booming Genentech plans 600 new hires in 2013. News

> Upstart Blaze banks $8.5M A round for new cancer surgery tech. Article

Pharma News

@FiercePharma: Sanofi's new 6-in-1 vaccine won backing from Europe's CHMP. Would compete with $GSK's Infanrix Hexa. News | Follow @FiercePharma

@EricPFierce: Elan CEO Martin gives shareholders a taste of honey. More | Follow @EricPFierce

@AlisonBFierce: The flu vaccine was effective in only 56% of those who received it, largely failing to protect against the elderly. More | Follow @AlisonBFierce

> Board, Vasella slammed for handling of retirement prize. Article

> Elan shareholders to get taste of $3.25B windfall. News

> Warburg persists in trying to unload Bausch + Lomb. Story